Change in use of proceeds from the global offering
Filed with HKEX · Stock code 2565 · · 7 pages · English
派格生物醫藥(杭州)股份有限公司 (A joint stock company incorporated in the People’s Republic of China with limited liability) (Stock Code: 2565) CHANGE IN USE OF PROCEEDS FROM THE GLOBAL OFFERING Reference is made to the prospectus issued by PegBio Co., Ltd. (the “Company”, together with its subsidiaries, the “Group”) dated May 19, 2025 (the “Prospectus”) in relation to the proposed use of net proceeds from the
Earlier from PegBio
- Proposed change of auditor
- Voluntary announcement core product Visepegenatide injection passed the preliminary review in accordance with the 2026 national reimbursement drug list adjustment
- Next Day Disclosure Return
- List of directors and their roles and functions
Later from PegBio
- 2026 Interim Report
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
Follow PegBio into a list and get an email when it puts out news.
Follow PegBio